Amanta Healthcare IPO will open on September 1, 2025 and close on September 3, 2025. It is a Book Built Issue through which the company plans to raise about ₹126 crores, comprising a fresh issue of ₹126 crores and an offer for sale of up to [.] equity shares with a face value of ₹10 each.

The IPO price band is fixed at ₹120 to ₹126 per share. The quota distribution is 35% for retail investors, 50% for QIBs, and 15% for HNIs. The IPO is scheduled to be listed on BSE and NSE on September 8, 2025, and the allotment date is September 4, 2025.

The company reported revenue of ₹276.09 crores in 2025 compared to ₹281.61 crores in 2024. Its profit increased to ₹10.50 crores in 2025 from ₹3.63 crores in 2024. Based on these financials, investors may consider applying for this IPO with a long-term view.

Business Overview

Amanta Healthcare Limited, founded in December 1994, is one of the leading pharmaceutical companies engaged in the development, manufacturing, and marketing of a wide range of sterile liquid products, mainly parenterals. These are packed in plastic containers using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. The company produces IV fluids, diluents, eye drops, and respiratory care solutions as part of its fluid therapy products.

Amanta Healthcare also manufactures irrigation solutions, first-aid items, and eye lubricants under its medical devices segment. The company markets its products through three business divisions: National Sales, International Sales, and Product Partnerships with various Indian and foreign pharmaceutical companies. Under its own brand, it produces more than 45 generic products and sells them in India through 320 distributors and stockists. As of March 31, 2025, the company employs a total of 1,718 people.